JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

Search

Smith & Nephew PLC ADR

Abrir

36.23 -0.77

Visão Geral

Variação de preço das ações

24h

Atual

Mín

36.19

Máximo

36.68

Indicadores-chave

By Trading Economics

Rendimento

100M

296M

Vendas

4.7M

3B

P/E

Médio do Setor

32.438

37.461

Rendimento de Dividendos

2.1

Margem de lucro

9.895

Funcionários

17,000

EBITDA

6.5M

723M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

-1.72% downside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

2.10%

2.33%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.9B

15B

Abertura anterior

37

Fecho anterior

36.23

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Smith & Nephew PLC ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de out. de 2025, 23:50 UTC

Ações em Alta

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 de out. de 2025, 23:25 UTC

Ganhos

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 de out. de 2025, 23:18 UTC

Ganhos

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 de out. de 2025, 22:20 UTC

Ganhos

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 de out. de 2025, 22:13 UTC

Ganhos

Wal-Mart de Mexico Net Profit Falls in 3Q

28 de out. de 2025, 21:38 UTC

Ganhos

Correction to Visa Sales Jump Article

28 de out. de 2025, 21:17 UTC

Ganhos

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 de out. de 2025, 21:07 UTC

Ganhos

Visa Sales Jump as Consumers Keep Spending -- Update

28 de out. de 2025, 21:02 UTC

Ganhos

Mondelez Tempers Outlook as Costs Rise

28 de out. de 2025, 23:51 UTC

Conversa de Mercado

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 de out. de 2025, 23:42 UTC

Conversa de Mercado

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 de out. de 2025, 23:02 UTC

Ganhos

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 de out. de 2025, 23:01 UTC

Ganhos

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 de out. de 2025, 22:46 UTC

Ganhos

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 de out. de 2025, 22:45 UTC

Ganhos

SK Hynix 3Q Net KRW12.6T >000660.SE

28 de out. de 2025, 22:44 UTC

Ganhos

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 de out. de 2025, 22:43 UTC

Ganhos

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 de out. de 2025, 22:42 UTC

Ganhos

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 de out. de 2025, 22:40 UTC

Ganhos

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 de out. de 2025, 22:40 UTC

Ganhos

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 de out. de 2025, 22:22 UTC

Ganhos

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 de out. de 2025, 22:22 UTC

Ganhos

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 de out. de 2025, 22:22 UTC

Ganhos

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 de out. de 2025, 22:20 UTC

Ganhos

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 de out. de 2025, 22:02 UTC

Ganhos

Review & Preview: Earnings Extravaganza -- Barrons.com

28 de out. de 2025, 21:42 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

28 de out. de 2025, 21:42 UTC

Conversa de Mercado
Ganhos

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 de out. de 2025, 21:20 UTC

Ganhos

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 de out. de 2025, 21:19 UTC

Ganhos

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 de out. de 2025, 21:18 UTC

Ganhos

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Comparação entre Pares

Variação de preço

Smith & Nephew PLC ADR Previsão

Preço-alvo

By TipRanks

-1.72% parte inferior

Previsão para 12 meses

Média 36.05 USD  -1.72%

Máximo 37.5 USD

Mínimo 34.65 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Smith & Nephew PLC ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

3 ratings

0

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

26.64 / 28.37Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat